Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission

Abstract

AbstractPurposeAmong high‐risk acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT), those with positive minimal residual disease (MRD) are susceptible to poor outcomes. Therefore, it is necessary to determine the most suitable preparatory regimen for these patients.MethodsData were analyzed from 141 patients who received allo‐HSCT and were diagnosed with high‐risk ALL. These patients underwent intensified conditioning regimens, including either total marrow and lymphoid irradiation (TMLI)‐etoposide (VP16)‐cyclophosphamide (CY) or busulfan (BU)‐VP16‐CY between October 2016 and November 2022. A total of 141 individuals were in complete remission (CR) before transplantation and, among all patients, 90 individuals exhibited a negative MRD status and 51 patients had a positive MRD status.ResultsIn patients who tested negative for MRD, the incidence of relapse within a 2‐year timeframe was 25.0% (24.8%–25.5%), compared with 32.2% (31.2%–33.2%) in MRD‐positive patients; however, this difference was not statistically significant. There were no significant differences in the 2‐year disease‐free survival (DFS) and 2‐year overall survival (OS) rates between the MRD‐negative and MRD‐positive groups (DFS: 67.2% (57.9%–78.1%) vs. 55.5% (42.6%–72.3%); OS: 69.0% (61.9%–88.2%) vs. 66.7% (53.9%–82.5%)). Furthermore, no notable variations were observed in the occurrence of transplant‐related mortality (TRM) and graft‐versus‐host disease (GVHD) across the two groups.ConclusionThis study reveals the benefits of TMLI‐VP16‐CY and BU‐VP16‐CY conditioning regimens in high‐risk ALL patients with CR and MRD‐positive status. A large‐scale prospective clinical trial is warranted in the future.